Trial record 1 of 1 for:    Prosopagnosia
Previous Study | Return to List | Next Study

The Effect of Oxytocin on Face Perception

This study has suspended participant recruitment.
(We are currently engaged in other behavioral study.)
Sponsor:
Collaborator:
Ben-Gurion University of the Negev
Information provided by (Responsible Party):
Ilan Shelef, Soroka University Medical Center
ClinicalTrials.gov Identifier:
NCT02091817
First received: January 26, 2014
Last updated: July 1, 2015
Last verified: July 2015
  Purpose

The purpose of this study is to determine whether oxytocin affect face perception


Condition Intervention Phase
Healthy
Congenital Prosopagnosia
Drug: Oxytocin
Drug: Placebo
Phase 0

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: The Behavioral and Neural Effects of Oxytocin on Face Perception in Congenital Prosopagnosia

Resource links provided by NLM:


Further study details as provided by Soroka University Medical Center:

Primary Outcome Measures:
  • Memory performance [ Time Frame: Day 2 (24 hours after encoding) ] [ Designated as safety issue: No ]
    At the day participants will administer the substance, they will view a set of faces, of which they will be tested about 24 hours later. The measures that will be tested are %accuracy and %dwell time of eye movements towards each region in the faces the participants saw.


Secondary Outcome Measures:
  • Mood measurement [ Time Frame: Day 1 (after oxytocin/placebo uptake) ] [ Designated as safety issue: No ]
    Participants will fill a PANAS mood questionnaire in order to monitor the effects of mood and fatigue of oxytocin/placebo. We will use ANOVA on the total score of the test in order to verify that differences in performance are not due to change in mood or fatigue after substance uptake.


Estimated Enrollment: 100
Study Start Date: November 2013
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Control group
Control group will be administered oxytocin and placebo, in a double-blind randomized order.
Drug: Oxytocin
Intervention will be examined on control group, and on experimental group as well.
Other Name: syntocinon
Drug: Placebo
Placebo will be given to control group and experimental group as well.
Experimental: congenital prosopagnosia
Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.
Drug: Oxytocin
Intervention will be examined on control group, and on experimental group as well.
Other Name: syntocinon
Drug: Placebo
Placebo will be given to control group and experimental group as well.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • normal or corrected to normal vision

Exclusion Criteria:

  • minors
  • pregnancy (according to a pregnancy test taken by subjects prior to participation)
  • a history of asthma or nasal polyps
  • cardiac disorders
  • hyponatremia
  • acute or chronic renal insufficiency
  • liver cirrhosis
  • neurological disease
  • other chronic disease
  • dementia, or lack of judgment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02091817

Locations
Israel
Soroka medical center
Beer Sheva, Israel
Sponsors and Collaborators
Soroka University Medical Center
Ben-Gurion University of the Negev
Investigators
Principal Investigator: Shelef Ilan, MD Soroka University Medical Center
Principal Investigator: Galia Avidan, Ph.D Ben-Gurion University of the Negev
  More Information

Publications:
Responsible Party: Ilan Shelef, Head of medical imaging at Soroka University Medical Center, Soroka University Medical Center
ClinicalTrials.gov Identifier: NCT02091817     History of Changes
Other Study ID Numbers: sor010712ctil, ISF, 384/10
Study First Received: January 26, 2014
Last Updated: July 1, 2015
Health Authority: Israel: Ministry of Health

Keywords provided by Soroka University Medical Center:
oxytocin
face
memory

Additional relevant MeSH terms:
Prosopagnosia
Agnosia
Nervous System Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Perceptual Disorders
Signs and Symptoms
Oxytocin
Oxytocics
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 01, 2015